Thermo Fisher Scientific Inc.TMO

Where TMO's Net Debt / EBITDA sits inside its own 10-year distribution, with the yearly high, low and average.

$709.18+5.03 (+0.71%)Previous close
NYSEHealthcare

TMO Net Debt / EBITDA: current value, 10-year range and year-by-year history

Net Debt / EBITDA History

Historically priceyAbove avgAround avgBelow avgHistorically cheap
TMO Net Debt / EBITDA historyTMO Net Debt / EBITDA from Dec 2023 to Sep 2026: low 2.4, high 3.48, latest 3.19.2.312.632.943.253.57Dec 23Jun 24Dec 24Sep 25Mar 26Sep 26med 2.62

TMO Net Debt / EBITDA by year

Yearly range of TMO’s net debt / ebitda from 2016 to 2026. Over the full period it ranged from 0.8 to 4.5, averaging 2.7.

TMO Net Debt / EBITDA — yearly low, average, high and year-end values
YearLowAverageHighYear-end
20263.23.33.53.2
20252.62.73.02.6
20242.42.52.62.4
20232.52.72.92.5
20222.22.42.52.3
20210.81.42.72.7
20201.21.92.41.2
20192.32.52.82.3
20182.73.23.82.7
20173.53.94.53.9
20163.63.63.63.6

Get notified when TMO Net Debt / EBITDA crosses a threshold

Free — one alert setup, notifications by push, Telegram, or Discord.

How many years of operating earnings it would take to pay off the company's net debt. The most common leverage ratio — higher means more financial risk and less flexibility.

Formula(Total Debt − Cash) / EBITDA
Full guide
How to read this chart

Watch the trend more than the level. Declining ratio = deleveraging, growing financial flexibility. Rising ratio = increasing leverage, which constrains dividends, buybacks, and future investment.

Key caveats
  • Sector context is essential: 3× is aggressive for a consumer brand but normal for a regulated utility. Always compare to sector peers.
  • Large acquisitions spike the ratio temporarily — check whether the integration plan credibly drives paydown.
Pro — up to 30-year history

Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.